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Abstract
Objective—This study examined the frequency and characteristics of alli® use among patients in 
eating disorder treatment facilities.
Method—Patients from five treatment centers completed the Survey of Eating and Related 
Behaviors. Diagnoses were determined from survey responses.
Results—Of 417 survey respondents, 26 (6.2%) reported a history of alli® use. Of those, 15 
(57.7%) met criteria for an eating disorder, including one of 29 patients (3.4%) with anorexia 
nervosa binge-purge subtype, six of 66 patients (9.1%) with full or subthreshold bulimia nervosa, 
four of 49 (8.2%) with binge eating disorder, one of six (16.7%) with purging disorder, and three 
of 80 (3.8%) with an eating disorder not otherwise specified.
Discussion—The results of this survey suggest that patients with eating disorders use alli®, 
albeit relatively uncommonly. Therefore, it is worthwhile for clinicians to inquire about alli® use 
when evaluating or treating these patients in any clinical setting.
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Introduction
Orlistat (Xenical®) has been available by prescription as a weight loss aid in the United 
States since 1999. In 2007, orlistat was also approved by the U.S. Food and Drug 
Administration (FDA) for nonprescription sales under the brand name of alli®, at one-half 
the daily dose of the prescription product. Currently, alli® is the only FDA-approved weight 
loss medication available over-the-counter. The majority of U.S. adults are currently 
classified as overweight or obese.1 For these individuals, the ability to readily obtain orlistat 
without a prescription may be advantageous. A substantial percentage of patients with an 
eating disorder engage in over-the-counter medication and herbal product use to promote 
weight loss2 and often continue these agents despite experiencing side effects.3 Therefore, 
the nonprescription availability of alli® warrants investigation of the frequency of use of this 
product in patients with eating disorders.
alli® is FDA-approved for nonprescription use in the United States by overweight patients 
ages 18 and older who are also on a reduced calorie, low-fat diet.4 alli® is formulated in 60 
mg capsules, which are to be taken within 1 hour of each fat-containing meal, up to three 
capsules per day.4 Orlistat’s pharmacological effect occurs through the inhibition of gastric 
and pancreatic lipases in the gastrointestinal tract, which prevents triglyceride hydrolysis and 
results in the decreased absorption of dietary fats, which are excreted through the feces.5 
alli® reduces dietary fat absorption by approximately 25% at the recommended dosage.4 
Efficacy increases in a dose-dependent manner up to approximately 300–400 mg per day, at 
which point a plateau is observed.5
Orlistat’s pharmacological actions occur locally in the gut6 and less than 2% of the drug is 
absorbed systemically.7 Therefore, the adverse effect profile associated with orlistat 
predominantly consists of a variety of gastrointestinal side effects such as soft stools, 
abdominal pain, steatorrhea, fecal urgency, flatulence, and other less common side effects, 
such as fecal incontinence.5 These adverse effects increase in response to the amount of fat 
consumed,5 although they typically diminish over time as patients gain experience using the 
medication.8 The alli® package label instructs patients to take a multiple vitamin on a daily 
basis at bedtime while using orlistat since absorption of fat-soluble vitamins may be 
reduced.4
Not uncommonly, patients with eating disorders misuse medications such as laxatives, 
diuretics, and diet pills to compensate for binge eating and/or to promote weight loss. Rates 
of laxative abuse among outpatients who have an eating disorder have been reported to be 
26.4% in the month prior to assessment in one study.9 Similarly, a study of patients with 
bulimia nervosa found that 64% of the sample had used diet pills, with 18% of the sample 
having used them in the month prior to the study assessment.10 This study also found the 
frequency of diuretic use to be 31%, with 21% of the sample having used them in the month 
Steffen et al. Page 2













prior to the study assessment. Therefore, it is possible that the nonprescription availability of 
alli® could lead to inappropriate use by patients with eating disorders. Indeed, a few case 
reports of use of orlistat by individuals with eating disorders have appeared in the literature. 
The majority of these case reports were published before orlistat became available over-the-
counter. Details of these cases are summarized in Table 1. This study was developed to 
quantify the frequency of alli® use among patients with eating disorder symptoms. 
Therefore, a treatment-seeking sample was examined and results are subsequently described.
Method
This study consisted of a survey that was administered at five eating disorder treatment 
facilities across the United States, including inpatient and outpatient facilities, between June 
of 2008 and March of 2009. Participants ages 12 and older who presented for evaluation or 
who were in ongoing treatment programs were eligible to participate. Those who completed 
the survey were compensated with a 10-dollar gift card. This study was supported through a 
research grant provided by GlaxoSmithKline.
Participants filled out the Survey of Eating and Related Behaviors, which is a 38-item self-
report questionnaire designed for this study to capture demographic and diagnostic 
information, binge eating frequency, and compensatory behavior methods and frequency. 
Participant’s self-reported height and weight were used to determine body mass index 
(BMI). Participants were not informed that the purpose of the study was to collect data on 
alli® use, and the questions concerning this were embedded among multiple other 
compensatory behavior questions (e.g. diuretics, Syrup of Ipecac). Probable current eating 
disorder diagnoses were determined based upon participants’ responses to survey items 
according to the criteria sets described in Table 2, which were used to assign each participant 
to one category.
The study was approved by the Institutional Review Boards for all five study sites and all 
participants provided written informed consent. In addition, participants ages 12 through 17 
were also required to provide written informed consent from a parent or legal guardian prior 
to taking the survey. All data were de-identified and maintained in a central database at the 
Neuropsychiatric Research Institute in Fargo, ND. Data were examined using SPSS Version 
17.
Data were examined descriptively. The small sample size of alli® users, and the discrepancy 
between the sample size of those who used alli® and those who had not prohibited 
performing valid statistical comparisons. Cases of nonresponse to items were treated as a 
negative response to the question to enhance manuscript readability and this is also indicated 
as appropriate in Tables.
Results
Participants
A total of 428 participants completed the survey. Of those, 417 completed the question 
regarding a history of alli® use and were explored in greater detail. Participants who had 
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prior bariatric surgery (N = 22) or who had an undeterminable BMI or bariatric surgery 
history (N = 44) were excluded from eating disorder diagnostic categorization and are 
presented separately. Survey numbers obtained from each of the study sites are as follows: 
Neuropsychiatric Research Institute, 99; University of Minnesota, 98; University of 
Chicago, 100; University of North Carolina, 48; Columbia University, 81.
Data were split on the basis of whether patients reported a history of alli® use or not, and are 
presented along with descriptive information for the complete sample in Table 3. The 
majority of the sample was female and Caucasian, with a mean age of 33.2 (±13.1) years 
and a mean BMI of 28.3 (±11.8) kg/m2. As expected in a treatment-seeking sample of 
patients with eating disorder symptoms, binge eating and compensatory methods such as 
laxatives, diuretics, and vomiting in the past month were relatively common, both in those 
who had used alli® and in those who had not. The group with a history of alli® use was 
found to have a higher percentage of patients who engaged in laxative, diuretic, diet pill, 
Syrup of Ipecac, and herbal fat burner use in the past month compared to the group who had 
not used alli®. Given the small sample size associated with the group who had used alli®, 
this observation cannot be confirmed statistically.
Frequency of alli® Use Among Patients with Eating Disorders
Of the 417 participants who responded to the question regarding a history of alli® use, 26 
(6.2%) reported that they had taken alli®. Table 4 summarizes the distribution of these 
patients according to diagnostic category. None of the 26 participants who reported 
symptoms consistent with anorexia nervosa restricting subtype (AN-R), and one of 29 
(3.4%) of those with anorexia nervosa binge-purge subtype (AN-BP) indicated a history of 
alli® use. The frequency of alli® use was higher in those who were categorized as having 
full or subthreshold bulimia nervosa (BN), where six of 66 (9.1%) reported that they had 
used the drug. Reported frequencies of alli® use for the other eating disorder diagnoses were 
four of 49 (8.2%) for full or subthreshold binge eating disorder (BED), one of six (16.7%) 
for purging disorder (PD), three of 80 (3.8%) for eating disorder not otherwise specified 
(EDNOS), one of 10 (10%) for overweight, four of 85 (4.7%) for obese, six of 44 (13.6%) of 
those with an unknown BMI or bariatric surgery history, and none of the 22 who had 
previously undergone bariatric surgery.
Six of the 26 (23.1%) participants who had used alli® reported that they had exceeded the 
maximum recommended dose of alli®. Data on the extent to which they exceeded the 
recommended dosage were not collected. The majority of these patients (N = 4) were in the 
BN diagnostic category. The mean duration of alli® use varied according to diagnostic 
category. These data are also presented in Table 4. Ten of the 26 patients who had used alli® 
(38.5%) reported that they had experienced side effects while using the drug. Summarized 
according to the descriptions provided by the participants, these included: diarrhea (N = 3), 
extreme diarrhea (N = 1), loose bowels (N = 1), stomach cramps and pain (N = 1), fat/oily 
diarrhea/stools (N = 2), gas (N = 2), racing/increased heart rate/palpitations (N = 2), panic 
(N = 1), dizziness/faintness (N = 1), and depression (N = 1).
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Characteristics of Patients Who Used alli®
Patients who reported a history of alli® use (N = 26) are further described in Table 5 
according to mean (±SD) BMI and age. alli® is indicated for adult patients who are 
overweight. The sample consisted of a small number of participants below age 18 (N = 20). 
One of these patients reported a history of alli® use and was found to be in the EDNOS 
category. Of the 26 participants who had used alli®, 10 (38.5%) had a BMI below 25 kg/m2 
at the time the survey was conducted. Given the retrospective nature of this survey, however, 
it is possible that the current BMI does not accurately represent the BMI at the time when 
alli® was used.
alli® Use in the Past Month
As shown in Table 4, of the 26 participants who reported that they had used alli®, 12 
(46.2%) had done so in the past month, consisting of those with BN (N = 4), BED (N = 1), 
EDNOS (N = 1), overweight (N = 1), obese (N = 3), and unknown BMI or bariatric surgery 
history (N = 2). Characteristics of patients who met criteria for an eating disorder (or 
EDNOS), and reported use of alli® in the past month (N = 6) are described in a brief case 
series according to their survey responses in Table 6. Ages ranged from 24 to 58 years old, 
BMI ranged from 18.9 to 42.9 kg/m2, most of the patients had a history of using other 
medications for weight loss or to compensate for binge eating, and all patients shared an 
extreme fear of weight gain.
Discussion
The population described in this study represents a treatment-seeking sample collected from 
five eating disorder treatment facilities across the United States. The study was comprised of 
patients who reported a variety of eating disorder symptoms and the sample represented a 
broad range of ages and BMIs. The results of this study suggest that a small subset of 
patients who are presenting for evaluation or are engaged in treatment in eating disorder care 
facilities have used alli®. The sample size associated with alli® use was too small in several 
of the diagnostic groups to draw definite conclusions. The rates of alli® use by patients with 
BN (9.1%) and BED (8.2%) suggest that clinicians should inquire about alli® use along with 
other compensatory behaviors when interviewing patients with eating disorders.
Patients with BN frequently use medications to compensate for binge eating through purging 
and/or to promote weight loss. Notably, several of the patients who indicated alli® use in this 
survey also engaged in the use of other weight loss methods. This is consistent with prior 
literature which suggests that a subset of patients with BN, as well as AN, use multiple 
purging methods. This practice has been associated with a higher lifetime prevalence of 
significant psychopathology, including mood, substance abuse, and cluster B personality 
disorders.15 The use of multiple purging methods has also been associated with a higher 
level of eating disorder severity,16 and a longitudinal investigation of a college sample 
showed that multiple purging methods at baseline predicted higher eating disorder severity at 
10 year follow-up.17 Although data addressing this issue are not available, as suggested by 
Cumella and colleagues (2), the risk of fat-soluble vitamin deficiency with alli® in patients 
with an eating disorder should be considered.
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Orlistat has been examined as a potential treatment for BED.18,19 Two controlled trials have 
shown the prescription dosage of orlistat (120 mg three times daily) to be efficacious for 
reducing body weight in patients who are obese with BED in combination with either 
cognitive behavioral therapy18 or a reduced calorie diet.19 However, prior case reports 
suggest that unmonitored use of this drug by patients who binge eat can be problematic. 
Given orlistat’s mechanism of action, gastrointestinal side effects are more pronounced 
following a high-fat meal. Therefore, using alli® as a strategy to compensate for a binge 
eating episode with high fat content could increase the adverse effect burden associated with 
the drug. To provide overweight or obese patients who have BED with the highest likelihood 
of effectiveness from orlistat, clinicians should consider prescribing it in the dosage used in 
the two extant controlled trials (120 mg three times daily) and providing careful monitoring 
in the context of a structured treatment program which should also include a diet and 
exercise component.
Ten of the 26 participants (38.5%) in this study who had used alli® reported that they had 
experienced side effects with the drug. The adverse effects listed by participants were 
generally consistent with what is expected with alli®, including a variety of gastrointestinal 
complaints. Cardiovascular complaints including palpitations and increased heart rate and 
psychiatric symptoms were each reported by two patients, which are not commonly 
attributed to orlistat use.5 From this survey, it is not possible to determine whether these 
symptoms were related to alli®, to an eating disorder, to concomitant medications, or to 
another etiology.
Along with the self-report nature of these data, other limitations of this study include the 
inability to determine the precise temporal sequence of alli® use in relationship to the use of 
other medications for weight loss and binge eating. Other than asking specifically for 
information on alli® use, this survey did not include questions designed to collect data 
regarding which specific types of laxatives, diuretics, and diet pills participants were using. 
Also, BMI at the time the survey was completed may not have represented the BMI at the 
time alli® was used since patients were asked if they had ever taken alli®. Therefore, alli® 
use in the past month may be of greatest relevance for this comparison. Nonpurging weight 
loss methods were not assessed, such as food restriction and excessive exercise. Data on 
diuretic use in the last month that were collected in this survey were assumed to be for 
weight loss purposes, although it is possible that patients were using them for hypertension 
or other medical purposes.
The results of this survey suggest that patients with eating disorders do use alli®, although in 
comparison to published prevalence rates of other inappropriate compensatory weight loss 
methods such as laxative misuse, the use of alli® appears relatively uncommon at this time. 
The cost to purchase alli®, in comparison to some of the other nonprescription medications, 
may be one factor that has led to the lower reported rates of misuse of this product relative to 
other medication classes. No serious adverse effects that could be clearly attributed to the 
drug were reported. Given the potential for the inappropriate use of this medication by 
patients with eating disorders, clinicians are encouraged to monitor for alli® use along with 
all other medications for weight loss in all clinical settings.
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TABLE 1
Prior literature on orlistat use by patients with eating disorders
Authors
Diagnosis, Current (C) 





(kg/m2) Description of Orlistat Use Comment
Fernandez-Aranda et al.11 BN-P, C: orlistat, Hx: 
vomiting, laxatives, food 
restriction
26 yo, 22 
kg/m2
Orlistat taken after bingeing, 
once to twice daily, totaling 
120–240 mg/day
Patient experienced soft stools 
as the only adverse effect of 
orlistat.
BN-P, C: orlistat, Hx: 
vomiting, laxatives, 
diuretics, food restriction
34 yo, 23.8 
kg/m2
Orlistat taken two-three times 
daily following binge 
episodes, totaling 240–360 
mg/day
No adverse effects were 
reported.
Cochrane and Malcolm12 BN-P, C: orlistat, 
phentermine, ephedrine, 
vomiting, herbal teas, fiber 
supplements, excessive 
coffee as a laxative, 







Orlistat taken after eating, 
240–480 mg each episode up 
to two-three times per week 
for 12 months. In the past 6 
months, frequency of use has 
decreased to once/week and 
prn for high fat binges.
Patient had bouts of diarrhea 
after taking orlistat, but never 
had fecal incontinence. Patient 
used orlistat at work when it is 
too difficult to vomit or use 
laxatives.
Malhotra and McElroy13 BN-P, C: orlistat, Hx: 
occassional use of laxatives 
to “relieve fullness”
49 yo, 45 
kg/m2
Orlistat was taken prn with 
binge eating
Patient was considered to have 
BED prior to orlistat use. Patient 
experienced 4–8 bowel 
movements per day along with 
fecal urgency, oily rectal 
spotting, and flatulence. 
Treatment providers felt orlistat 
reinforced binge eating behavior 
and encouraged patient to 
discontinue use.
Hagler-Robinson14 BED 45 yo, BMI 
< 27 kg/m2
Orlistat was taken in double 
the indicated dosage and more 
frequently than recommended. 
Patient did not limit fat intake, 
often purposefully binge 
eating high fat foods after 
taking orlistat.
Patient experienced adverse 
effects including oily spotting 
which made her “feel less 
guilty” about binge eating. She 
also experienced cramping and 
soreness during excretion. 
During treatment with cognitive-
behavioral therapy, patient 
discontinued orlistat use. 
Authors discuss the similarity of 
this orlistat use to BN.
Notes: BED, binge eating disorder; BMI, body mass index; BN, bulimia nervosa; BN-P, bulimia nervosa, purging subtype; C, currently using; Hx, 
history of use; prn, only taken “as needed”; yo, year-old.
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TABLE 2
Criteria for assigning cases to probable eating disorder diagnoses
Anorexia nervosa, 
restricting type
1 Current BMI ≤17.5 kg/m2
2 No binge eating, vomiting, laxative or diuretic use in the past month
3 No history of bariatric surgery.
Anorexia nervosa, binge/
purge type
1 Current BMI ≤17.5 kg/m2
2 Any binge eating, vomiting, laxative, or diuretic use within the past month
3 No history of bariatric surgery
Bulimia nervosa and 
subthreshold bulimia 
nervosa, purging type
1 BMI > 17.5 kg/m2
2 A minimum average frequency of binge eating of once per week over the past month
3 A minimum average frequency of vomiting, laxative, or diuretic use of once per week over the 
past month
4 No history of bariatric surgery
Binge eating disorder and 
subthreshold binge eating 
disorder
1 BMI > 17.5 kg/m2
2 A minimum average frequency of binge eating of once per week over the past month
3 No vomiting, laxative, or diuretic use in the past month
4 No history of bariatric surgery
Purging disorder 1 BMI > 17.5 kg/m2
2 No binge eating in the past month
3 A minimum average frequency of vomiting, laxative, or diuretic use of once per week
4 No history of bariatric surgery
Eating disorder not 
otherwise specified
1 BMI ≤ 25 kg/m2
2 Does not meet any other diagnostic criteria
3 No history of bariatric surgery
Overweight 1 BMI > 25 but < 30 kg/m2
2 Does not meet any other diagnostic criteria
3 No history of bariatric surgery
Obese 1 BMI ≥ 30 kg/m2
2 Does not meet any other diagnostic criteria
3 No history of bariatric surgery
History of bariatric surgery 1 Status-post bariatric surgery
BMI or bariatric surgery 
history unreported
1 Participant did not report current height, weight, or both
2 No history of bariatric surgery or unknown history of bariatric surgery
Note: BMI, body mass index.
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TABLE 3
Characteristics of sample according to history of alli® use
History Use of alli® N (%)a,b or 
Mean ± SD (Range)b
No History of Complete alli® Use N 
(%)a,b or Mean ± SD (Range)b
Sample N (%)a,b or Mean ± SD 
(Range)b
N 26 (6.2) 391 (93.8) 417
Age (years) 39 ± 13.9 (15–61) 33 ± 13 (13–69) 33.2 ± 13.1 (13–69)
Age < 18 years 1 (3.8) 19 (4.9) 20 (4.8)
BMI (kg/m2) 28.8 ± 10 (14.9–44.6) 28.3 ± 11.9 (10.6–70.9) 28.3 ± 11.8 (10.6–70.9)
BMI < 25 kg/m2 10 (38.5) 194 (49.6) 204 (48.9)
Gender
 Female 22 (84.6) 346 (88.5) 368 (88.2)
 Male 1 (3.8) 34 (8.7) 35 (8.4)
Race/ethnicity
 White 17 (65.4) 311 (79.5) 328 (78.7)
 African American 5 (19.2) 30 (7.7) 35 (8.4)
 Native American 0 (0) 2 (.51) 2 (.48)
 Hispanic 3 (11.5) 29 (7.4) 32 (7.7)
 Asian 0 (0) 4 (1) 4 (1)
 Other/unknown 1 (3.8) 14 (3.6) 15 (3.6)
Eating disorder behaviors in the past monthc
 Binge eating 16 (61.5) 230 (58.8) 246 (59)
 Self-induced vomiting 10 (38.5) 137 (35) 147 (35.3)
 Laxative use 7 (26.9) 52 (13.3) 59 (14.1)
 Diet pill use 15 (57.7) 46 (11.8) 61 (14.6)
 Diuretic use 9 (34.6) 26 (6.6) 35 (8.4)
 Syrup of Ipecac use 2 (7.7) 4 (1) 6 (1.4)
 alli® use 12 (46.2) — 12 (2.9)
 Herbal “fat burner” use 10 (38.5) 56 (14.3) 66 (15.8)
a
Percentages in each column were computed as the number of positive responses divided by the total sample in the respective alli® use group or 
the complete sample (N = 26, N = 391, or N = 417). Only participants who responded to the question asking if they had ever used alli® are 
included.
b
Values based upon available data; not all participants completed all questions.
c
Missing data were treated as a negative response to the question.
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